


## Muraglitazar

## Chemical Properties

CAS No. :	331741-94-7
Formula:	C <sub>29</sub> H <sub>28</sub> N <sub>2</sub> O <sub>7</sub>
Molecular Weight:	516.54
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Muraglitazar (BMS-298585) is a PPAR $\alpha/\gamma$ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPAR $\alpha$ and PPAR $\gamma$ with EC <sub>50</sub> of 320 nM and 110 nM respectively.
Targets(IC <sub>50</sub> )	PPAR

## Solubility Information

Solubility	DMSO: 128.8 mg/mL (249.35 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.39 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.936 mL	9.6798 mL	19.3596 mL
5 mM	0.3872 mL	1.936 mL	3.8719 mL
10 mM	0.1936 mL	0.968 mL	1.936 mL
50 mM	0.0387 mL	0.1936 mL	0.3872 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8): 1181-1195.

Cox SL. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc). 2005;41(9):579-587.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481